Large gap with delayed quotes
|
Last quote
12/27/2024 -
17:20:00
|
Bid
12/27/2024 -
15:59:59
|
Bid Volume |
Ask
12/27/2024 -
15:59:59
|
Ask Volume |
|---|---|---|---|---|
|
7.39
-0.27
(
-3.52% )
|
7.39
|
93,000 |
7.40
|
1,600 |
Analysis date: 24.12.2024
Global Evaluation
Negativ
Negativ
The stock is classified in the negative zone since 20.12.2024.
Interest
Weak
Weak
Weak interest since 24.12.2024.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 20.12.2024 at a price of 6.03.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, at its current price the stock is strongly overvalued.
MT Tech Trend
Positive
Positive
The forty day Medium Term Technical Trend is positive since 24.12.2024. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 6.714.
4wk Rel Perf
19.79%
19.79%
The four week relative overperformance versus SP500 is 19.79%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 3.49%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 7.04%.
Mkt Cap in $bn
2.73
2.73
With a market capitalization between $2 & $8bn, RECURSION PHARMACEUTICALS A is considered a mid-cap stock.
G/PE Ratio
0.25
0.25
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.6 indicates that investors must pay a substantial premium for the estimated growth potential: >50% premium.
LT P/E
-5.59
-5.59
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
1.42%
1.42%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
6
6
Over the last seven weeks, an average of 6 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
305
305
For 1% of index variation, the stock varies on average by 3.05%.
Correlation
0.40
0.40
Stock movements are strongly independent of index variations.
Value at Risk
5.64
5.64
The value at risk is estimated at USD 5.64. The risk is therefore 77.85%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
23.07.2021
23.07.2021